Sellas Life Sciences Faces Stock Decline Despite Positive Trial Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 29 2025
0mins
Sellas Life Sciences Group Inc (SLS) saw its stock price drop by 5.47% as it crossed below the 5-day SMA, despite the broader market's positive performance with the Nasdaq-100 up 1.86% and the S&P 500 up 0.83%.
The decline comes amid strong investor sentiment surrounding the company's Phase 3 Regal trial for acute myeloid leukemia (AML), which has reached 78 out of 80 required events. The trial's success could significantly enhance the median overall survival of GPS treatment, potentially extending it from 8 months to 12.6 months. Additionally, MassMutual's recent acquisition of a small stake in Sellas indicates growing interest in the company, although the stock's recent price movement suggests sector rotation may be at play.
Despite the stock's decline, the overall market sentiment remains optimistic, with many investors holding their positions in anticipation of positive trial results. The company's financial stability, bolstered by recent shareholder approvals for incentive plans, further supports its potential for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLS
Wall Street analysts forecast SLS stock price to fall
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.940
Low
7.00
Averages
7.25
High
7.50
Current: 13.940
Low
7.00
Averages
7.25
High
7.50
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MassMutual Acquires Small Stake in Sellas Life Sciences
- MassMutual Stake Acquisition: MassMutual Private Wealth & Trust disclosed ownership of 24 shares of Sellas Life Sciences (SLS) valued at $354.24 as of June 30, indicating growing interest in the company ahead of its acute myeloid leukemia (AML) trial results.
- Clinical Trial Progress: The Phase 3 Regal trial has reached 78 out of 80 required events, nearing a critical analysis point, and if successful, could extend the median overall survival of GPS treatment from 8 months to 12.6 months, significantly enhancing the company's competitive position in the market.
- Retail Investor Interest: The CEO's Independence Day post on social media sparked retail investor chatter about potential buyouts, reflecting heightened market interest in the company's future partnership opportunities, which has contributed to the stock's recent price surge.
- Shareholder Approval of Incentive Plan: Sellas recently received shareholder approval for a 20 million-share increase to its 2023 Equity Incentive Plan, with CEO Stergiou awarded 1.065 million restricted stock units, demonstrating the company's commitment to executive incentives and confidence in future growth.
See More
Sellas Life Sciences Stock Gains Retail Trader Favor Amid Bullish Sentiment
- Retail Trader Enthusiasm: In a poll of 3,400 users, Sellas Life Sciences (SLS) garnered 50% of the votes, significantly outpacing Ondas Holdings at 24% and ImmunityBio at 18%, indicating strong investor confidence in its future potential.
- Clinical Trial Progress: Sellas' Phase 3 Regal trial in acute myeloid leukemia (AML) has reached 78 of the 80 events needed for final analysis, making the next two events critical catalysts that could drive stock price volatility.
- Acquisition Speculation: CEO Angelos Stergiou's optimistic remarks on social media and gratitude towards strategic partners have intensified market speculation regarding potential buyouts, likely attracting more investor interest.
- Significant Market Value Increase: Sellas' market value surged from $73 million at the start of 2024 to over $1.5 billion by mid-2026, reflecting heightened investor attention around the Regal readout, while the company ended Q1 with $107.1 million in cash, showcasing a robust financial position.
See More
U.S. Bank Earnings Season Set to Begin
- Earnings Season Begins: Major U.S. banks are set to report Q2 earnings starting July 14, with market participants eager to gauge the strength of economic recovery, which could significantly influence investor confidence and market direction.
- Fed Minutes Release: The minutes from the Federal Reserve's June meeting will be released on Wednesday, with expectations that interest rates will remain steady at 3.5% to 3.75%, as investors look for guidance from new Chair Kevin Warsh on future policy, potentially impacting market expectations.
- Disappointing Jobs Data: U.S. payrolls increased by 57,000 in June, falling short of Wall Street expectations, which has lowered the odds of a July rate hike to 21.9%, highlighting the fragility of the economic recovery.
- Geopolitical Tensions: The funeral of Iran's former leader has tightened shipping flows through the Strait of Hormuz, potentially affecting global oil supply, as Brent crude prices fell by about 0.42% to $71.82 per barrel amid these developments.
See More
Biotech Companies See Significant Stock Gains
- SL Science Surge: SL Science Holding Limited (SLBT) saw its stock price soar over 50% after its Nasdaq listing, closing at $5.99, reflecting strong market interest in its innovative cellular and gene therapies targeting significant unmet medical needs like pancreatic cancer and glioblastoma.
- Chemomab's Clinical Progress: Chemomab Therapeutics Ltd. (CMMB) experienced a stock increase of over 30%, closing at $2.27, as its lead drug candidate Nebokitug prepares for a Phase 3 trial in primary sclerosing cholangitis, highlighting its potential in treating fibro-inflammatory diseases.
- Propanc's Buyback Initiative: Propanc Biopharma Inc. (PPCB) announced a share repurchase program of up to $500,000, leading to a 22.92% stock increase to $1.77, indicating confidence in its cancer treatment candidate PRP and plans for a first-in-human study in advanced cancer patients.
- Tectonic's Clinical Trial Updates: Tectonic Therapeutic Inc. (TECX) saw its stock rise over 15%, closing at $37.93, as its lead candidates TX45 and TX2100 progress in clinical trials, with significant data expected in late 2026 or early 2027, potentially driving future growth.
See More
Sellas Life Sciences Sees Optimistic Clinical Trial Predictions
- Clinical Trial Success Probability: The clinical trials prediction market has priced 'YES' contracts for GPS (galinpepimut-S) in acute myeloid leukemia (AML) at $0.83, indicating an 83% probability of success, which could provide potential support for Sellas' stock price.
- Regal Trial Progress: Sellas' Regal trial has reached 78 out of 80 events needed for final analysis, and if GPS can extend the median overall survival from 8 months to 12.6 months, it will be deemed successful, significantly enhancing the company's market position in AML treatment.
- Strong Investor Sentiment: Despite a 10% drop in SLS stock to $13.27 on Monday, a Stocktwits poll revealed that 47% of investors are holding and 35% are buying more, indicating strong confidence among retail investors in the stock.
- Cash Flow and Shareholder Support: Sellas ended Q1 with $107.1 million in cash and raised an additional $28.7 million through warrant exercises, while shareholders approved a 20 million-share increase to its equity incentive plan, strengthening the company's financial foundation for future growth.
See More
Retail Traders Continue to Hold SLS Stock Amid Bullish Sentiment
- Strong Holding Sentiment: A Stocktwits poll reveals that 49% of investors are holding SLS stock while 35% are buying more, indicating robust confidence among retail traders in Sellas Life Sciences despite a 292% surge in the stock during the first half of the year.
- Clinical Trial Progress: Sellas' Phase 3 Regal trial for AML has reached 78 of the 80 events required for final analysis, with CEO Stergiou noting that the delay is a positive signal suggesting patients are living longer than expected, which could enhance the drug's market potential.
- Market Capital Growth: Sellas' market cap has skyrocketed from $73 million at the start of 2024 to over $1.5 billion by mid-2026, reflecting strong performance in the capital markets, while the company ended Q1 with $107.1 million in cash, bolstering its financial stability.
- Shareholder Support and Incentive Plans: Shareholders recently approved a 20 million-share increase to the 2023 Equity Incentive Plan, and Stergiou was awarded 1.065 million restricted stock units, further solidifying his stake in the company and reflecting management's confidence in future growth.
See More
MassMutual Acquires Small Stake in Sellas Life Sciences
- MassMutual Stake Acquisition: MassMutual Private Wealth & Trust disclosed ownership of 24 shares of Sellas Life Sciences (SLS) valued at $354.24 as of June 30, indicating growing interest in the company ahead of its acute myeloid leukemia (AML) trial results.
- Clinical Trial Progress: The Phase 3 Regal trial has reached 78 out of 80 required events, nearing a critical analysis point, and if successful, could extend the median overall survival of GPS treatment from 8 months to 12.6 months, significantly enhancing the company's competitive position in the market.
- Retail Investor Interest: The CEO's Independence Day post on social media sparked retail investor chatter about potential buyouts, reflecting heightened market interest in the company's future partnership opportunities, which has contributed to the stock's recent price surge.
- Shareholder Approval of Incentive Plan: Sellas recently received shareholder approval for a 20 million-share increase to its 2023 Equity Incentive Plan, with CEO Stergiou awarded 1.065 million restricted stock units, demonstrating the company's commitment to executive incentives and confidence in future growth.
See More
Sellas Life Sciences Stock Gains Retail Trader Favor Amid Bullish Sentiment
- Retail Trader Enthusiasm: In a poll of 3,400 users, Sellas Life Sciences (SLS) garnered 50% of the votes, significantly outpacing Ondas Holdings at 24% and ImmunityBio at 18%, indicating strong investor confidence in its future potential.
- Clinical Trial Progress: Sellas' Phase 3 Regal trial in acute myeloid leukemia (AML) has reached 78 of the 80 events needed for final analysis, making the next two events critical catalysts that could drive stock price volatility.
- Acquisition Speculation: CEO Angelos Stergiou's optimistic remarks on social media and gratitude towards strategic partners have intensified market speculation regarding potential buyouts, likely attracting more investor interest.
- Significant Market Value Increase: Sellas' market value surged from $73 million at the start of 2024 to over $1.5 billion by mid-2026, reflecting heightened investor attention around the Regal readout, while the company ended Q1 with $107.1 million in cash, showcasing a robust financial position.
See More
U.S. Bank Earnings Season Set to Begin
- Earnings Season Begins: Major U.S. banks are set to report Q2 earnings starting July 14, with market participants eager to gauge the strength of economic recovery, which could significantly influence investor confidence and market direction.
- Fed Minutes Release: The minutes from the Federal Reserve's June meeting will be released on Wednesday, with expectations that interest rates will remain steady at 3.5% to 3.75%, as investors look for guidance from new Chair Kevin Warsh on future policy, potentially impacting market expectations.
- Disappointing Jobs Data: U.S. payrolls increased by 57,000 in June, falling short of Wall Street expectations, which has lowered the odds of a July rate hike to 21.9%, highlighting the fragility of the economic recovery.
- Geopolitical Tensions: The funeral of Iran's former leader has tightened shipping flows through the Strait of Hormuz, potentially affecting global oil supply, as Brent crude prices fell by about 0.42% to $71.82 per barrel amid these developments.
See More
Biotech Companies See Significant Stock Gains
- SL Science Surge: SL Science Holding Limited (SLBT) saw its stock price soar over 50% after its Nasdaq listing, closing at $5.99, reflecting strong market interest in its innovative cellular and gene therapies targeting significant unmet medical needs like pancreatic cancer and glioblastoma.
- Chemomab's Clinical Progress: Chemomab Therapeutics Ltd. (CMMB) experienced a stock increase of over 30%, closing at $2.27, as its lead drug candidate Nebokitug prepares for a Phase 3 trial in primary sclerosing cholangitis, highlighting its potential in treating fibro-inflammatory diseases.
- Propanc's Buyback Initiative: Propanc Biopharma Inc. (PPCB) announced a share repurchase program of up to $500,000, leading to a 22.92% stock increase to $1.77, indicating confidence in its cancer treatment candidate PRP and plans for a first-in-human study in advanced cancer patients.
- Tectonic's Clinical Trial Updates: Tectonic Therapeutic Inc. (TECX) saw its stock rise over 15%, closing at $37.93, as its lead candidates TX45 and TX2100 progress in clinical trials, with significant data expected in late 2026 or early 2027, potentially driving future growth.
See More
Sellas Life Sciences Sees Optimistic Clinical Trial Predictions
- Clinical Trial Success Probability: The clinical trials prediction market has priced 'YES' contracts for GPS (galinpepimut-S) in acute myeloid leukemia (AML) at $0.83, indicating an 83% probability of success, which could provide potential support for Sellas' stock price.
- Regal Trial Progress: Sellas' Regal trial has reached 78 out of 80 events needed for final analysis, and if GPS can extend the median overall survival from 8 months to 12.6 months, it will be deemed successful, significantly enhancing the company's market position in AML treatment.
- Strong Investor Sentiment: Despite a 10% drop in SLS stock to $13.27 on Monday, a Stocktwits poll revealed that 47% of investors are holding and 35% are buying more, indicating strong confidence among retail investors in the stock.
- Cash Flow and Shareholder Support: Sellas ended Q1 with $107.1 million in cash and raised an additional $28.7 million through warrant exercises, while shareholders approved a 20 million-share increase to its equity incentive plan, strengthening the company's financial foundation for future growth.
See More
Retail Traders Continue to Hold SLS Stock Amid Bullish Sentiment
- Strong Holding Sentiment: A Stocktwits poll reveals that 49% of investors are holding SLS stock while 35% are buying more, indicating robust confidence among retail traders in Sellas Life Sciences despite a 292% surge in the stock during the first half of the year.
- Clinical Trial Progress: Sellas' Phase 3 Regal trial for AML has reached 78 of the 80 events required for final analysis, with CEO Stergiou noting that the delay is a positive signal suggesting patients are living longer than expected, which could enhance the drug's market potential.
- Market Capital Growth: Sellas' market cap has skyrocketed from $73 million at the start of 2024 to over $1.5 billion by mid-2026, reflecting strong performance in the capital markets, while the company ended Q1 with $107.1 million in cash, bolstering its financial stability.
- Shareholder Support and Incentive Plans: Shareholders recently approved a 20 million-share increase to the 2023 Equity Incentive Plan, and Stergiou was awarded 1.065 million restricted stock units, further solidifying his stake in the company and reflecting management's confidence in future growth.
See More
